Healthcare provider profile · identity verified

John D Blackman, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · COLUMBUS, OH · NPI 1174694749

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John D Blackman, MD received $72.61 in general payments during 2025 across 2 reported records.

Insulet Corporation accounted for 58.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$72.61

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Insulet Corporation	Unresolved — no canonical attribution shown	$42.24	58.2%	1	2025
Medtronic, Inc.	Medtronic, Inc. exact · evidence 2025-07-22	$30.37	41.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$72.61	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Omnipod Normalized: omnipod	Device	Insulet Corporation	$42.24	1	2025
Source payment records 2025-02-12 · Insulet Corporation · $42.24 · Open Payments source
MINIMED 780G Normalized: minimed 780g	Device	Medtronic, Inc.	$30.37	1	2025
Source payment records 2025-03-18 · Medtronic, Inc. · $30.37 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	563	150
Trulicity	Dulaglutide	303	71
Atorvastatin Calcium	Atorvastatin Calcium	302	105
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	217	80
Ozempic	Semaglutide	210	57
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	194	24
Metformin Hcl Er	Metformin Hcl	174	57
Metformin Hcl	Metformin Hcl	173	58
Jardiance	Empagliflozin	168	45
Synthroid	Levothyroxine Sodium	120	35
Amlodipine Besylate	Amlodipine Besylate	106	33
Mounjaro	Tirzepatide	84	22
Lisinopril	Lisinopril	83	25
Tresiba Flextouch U-100	Insulin Degludec	83	29
Rosuvastatin Calcium	Rosuvastatin Calcium	73	27
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	69	21
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	69	27
Alendronate Sodium	Alendronate Sodium	68	23
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	68	31
Humalog Kwikpen U-100	Insulin Lispro	67	30
Humulin R U-500 Kwikpen	Insulin Regular, Human	67	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	62	18
Xultophy 100-3.6	Insulin Degludec/Liraglutide	60	13
Novolog Flexpen	Insulin Aspart	59	23
Ezetimibe	Ezetimibe	55	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	55	25
Glipizide	Glipizide	54	14
Losartan Potassium	Losartan Potassium	54	20
Fiasp Flextouch	Insulin Aspart (Niacinamide)	50	21
Hydrocortisone	Hydrocortisone	44	11
Methimazole	Methimazole	39	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	38	18
Humalog	Insulin Lispro	38	15
Insulin Lispro Kwikpen U-100	Insulin Lispro	37	19
Insulin Lispro	Insulin Lispro	36	12
Novolog	Insulin Aspart	36	16
Kerendia	Finerenone	35	suppressed
Farxiga	Dapagliflozin Propanediol	34	suppressed
Gabapentin	Gabapentin	33	13
Insulin Syringe	Syringe And Needle,insulin,1ml	33	13
Lantus	Insulin Glargine,hum.Rec.Anlog	33	11
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	33	13
Levemir Flexpen	Insulin Detemir	31	12
Simvastatin	Simvastatin	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Desmopressin Acetate	Desmopressin Acetate	24	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	24	suppressed
Calcitriol	Calcitriol	23	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	23	suppressed
Testosterone Cypionate	Testosterone Cypionate	21	suppressed
Vascepa	Icosapent Ethyl	21	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	20	suppressed
Lyumjev	Insulin Lispro-Aabc	20	suppressed
Lyumjev Kwikpen U-100	Insulin Lispro-Aabc	20	suppressed
Tresiba Flextouch U-200	Insulin Degludec	20	suppressed
Levemir	Insulin Detemir	19	suppressed
Cabergoline	Cabergoline	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Dexamethasone	Dexamethasone	18	15
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	18	suppressed
Metoprolol Succinate	Metoprolol Succinate	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Testosterone	Testosterone	17	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Furosemide	Furosemide	15	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Novolin N	Insulin Nph Human Isophane	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Omnipod Dash Pods (Gen 4)	Insulin Pump Cart,cont Inf,bt	14	suppressed
Icosapent Ethyl	Icosapent Ethyl	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Prolia	Denosumab	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Admelog Solostar	Insulin Lispro	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	11	suppressed
Prednisone	Prednisone	11	suppressed
Ramipril	Ramipril	11	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$72.61 · 2 records	Insulet Corporation	MINIMED 780G, Omnipod	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error